Follow Mint Lounge

Latest Issue

Home > Smart Living> Innovation > Covid-19: Pfizer or Sputnik? The race to inject prompts calls for choice

Covid-19: Pfizer or Sputnik? The race to inject prompts calls for choice

While doses remain scarce for now, health authorities in some countries have begun catering to people’s concerns about vaccine differences

A pharmacist prepares a dose of the Pfizer BioNtech Covid-19 vaccine at a mass vaccination site at Fenway Park in Boston, Massachusetts, U.S. on 29 January, 2021. (Photo credit: Adam Glanzman/Bloomberg)
A pharmacist prepares a dose of the Pfizer BioNtech Covid-19 vaccine at a mass vaccination site at Fenway Park in Boston, Massachusetts, U.S. on 29 January, 2021. (Photo credit: Adam Glanzman/Bloomberg)

Few people care who made their flu shot or their childhood immunizations against a range of deadly diseases. Covid changed that, turning vaccine makers into household names and prompting calls for choice.

Doses remain scarce for now, amid a global scramble inflamed by a dispute between the European Union and British drugmaker AstraZeneca Plc. Most of the more than 90 million people who’ve gotten a shot consider themselves lucky for any protection against the pandemic. But vaccines are proliferating, with positive trial data from Johnson & Johnson and Novavax Inc. placing their candidates next in line for approval.

Health officials will have to figure out how to allocate all these different vaccines. Many people who’ve been boning up on efficacy rates, dosing schedules or side effects want to decide for themselves. If the options are a shot from a Western drugmaker that’s been vetted by an independent regulator or one from a Russian or Chinese lab with lesser transparency, that desire is even greater.

“We demand the government to provide people the freedom of choice,” said Gergely Arato, a member of the opposition Democratic Coalition party in Hungary.

Hungary broke ranks with other EU members to approve Russia’s Sputnik V and a vaccine from China’s Sinopharm Group Ltd. alongside the three shots cleared by Europe’s drug regulator -- from Pfizer Inc., Moderna Inc. and AstraZeneca. While Prime Minister Viktor Orban is technically offering choice, his promotion of the Chinese and Russian shots is endangering people’s “willingness to get vaccinated,” Arato said at a press conference this month.

In the US, where the only two shots authorized so far -- from Pfizer and Moderna -- use similar technology and demonstrated virtually identical test results, choice may matter less for now. Elsewhere, however, some health authorities have begun catering to people’s concerns about vaccine differences.

Dubai, Hong Kong

In Dubai, residents older than 60 or with pre-existing conditions can access the shot Pfizer developed with BioNTech SE, or the one from Sinopharm.

In Hong Kong, officials ordered enough doses of vaccines from Pfizer-BioNTech, Sinovac Biotech Ltd. and AstraZeneca -- along with plans to secure a fourth option -- to cover the 7.5 million residents.

The Pfizer shot will be available at community vaccination centers, with the Sinovac and Astra options offered at private hospitals and clinics, and people will be given the choice of which they want to receive. That’s important in Hong Kong, where some people are wary of taking a Chinese-made vaccine.

“If residents don’t want to take a certain vaccine, they can choose to get the shots at another time and another location,” chief executive Carrie Lam said in December.

Supplies are so tight in most of the world that choice remains impossible. Those getting shots often have no idea which one they’ll receive until they walk through the door of a vaccination center or doctor’s office. But that could change if vaccines from the likes of J&J, Novavax and CureVac NV come on stream in the coming weeks, and as pharma giants like Sanofi and Novartis AG lend their heft to the production effort.

EU approval

Even if they don’t offer choice, health officials have to decide who gets what. At the Cleveland Clinic, Cassandra Calabrese has been telling patients to take whatever vaccine they get offered, even though some have been asking her which one she’d recommend. “Things may be different as more are approved,” she said in an email.

The European Union, criticized for its slow rollout of the Pfizer-BioNTech and Moderna vaccines, expanded its offerings Friday by approving AstraZeneca’s shot. In a sign of the growing tide of people wanting to choose, the approval came after days of pitched debate about the shot’s efficacy, with Germany’s immunization commission recommending against its use in seniors.In the UK, where infections and fatalities are much higher than in Hong Kong, health authorities are prioritizing the quick inoculation of as many people as possible. The second dose of two-shot vaccines is being delayed in an effort to get first injections into as many arms as possible. Other countries are considering similar steps. Distribution is based on “supply and logistics, such as availability of very cold freezers,” a UK Department of Health spokesman said by email. The Pfizer-BioNTech and Moderna shots must be kept frozen for long-term storage, while refrigeration suffices for the AstraZeneca vaccine.

Efficacy rates

Although the UK has set a priority list for vaccine recipients -- starting with the oldest, most vulnerable people -- it doesn’t allocate the different shots based on a person’s profile, the agency added. So one 80-year-old patient might receive the AstraZeneca shot while someone else with the same age and health conditions might get the Pfizer one.Some Britons are expressing a preference on the grounds of patriotism rather than what they might have read about different efficacy rates or side effects. Never mind that the US company’s vaccine was 95% effective in large trials, compared with an average of 70% for AstraZeneca’s shot.“They’re saying they want to wait for the British one,” Jimmy Whitworth, a professor of public health at the London School of Hygiene and Tropical Medicine, said in a phone interview. “I think that it’s purely a nationalistic viewpoint.”

©2021 Bloomberg L.P.

Next Story